Recent advancements in life sciences, spanning genomics, biotechnology and personalised medicine, and breakthroughs such as gene editing, mRNA, and AI-driven drug discovery have been enabling diagnoses, more effective treatments and a shift toward precision healthcare. As a result, human health is poised to improve, with extended life expectancy and enhanced quality of life.
This session will examine how investment can target the infrastructure and innovation needed for breakthroughs and help turn revolutionary scientific discoveries into future healthcare solutions.
China's life sciences and biomedicine have been rapidly developing and gradually entering the forefront of global industry and innovation. However, investing in future health is not just about drugs and healthcare, but also includes investments in specific sub-sectors related to culture, sports, tourism, etc. This session will also examine health investment from a broader perspective and strive to illustrate a wider range of investment opportunities.
Questions to be addressed
- How can Investors help provide the financial resources needed to support long-term research, clinical trials and the commercialisation of new medical technologies?
- How to enable startups and research institutions to scale innovations and bring cutting-edge therapies and diagnostics to market?
- How can Investment in life sciences help improve lives in developing countries by funding affordable innovations, strengthening local research capacity, and expanding access to life-saving diagnostics, treatments and vaccines?
- In industries such as culture, sports, and tourism, which emerging investment opportunities are closely related to public health, and which cross-sectors (such as sports and medical tourism) are closely related to international investment and trade?
- How to promote new technology and business model innovation through forward-looking investment to promote a healthier lifestyle in the future?
Speakers
- Nader Naini, Managing Partner, Frazier Healthcare Partners
- Robert Nelsen, Co-founder and Managing Director, ARCH Venture Partners
- Shaikha Nasser Al Nowais, Secretary-General Elect, UN Tourism; Corporate Vice President of Owner Relationship Management, Rotana (tbc)
- Ugur Sahin, Co-Founder and Chief Executive Officer, BioNTech
- Duane Kuang, Founding Managing Partner, Qiming Venture Partners, China
- Li Ning, Executive Chairman and Joint Chief Executive Officer, LI-NING Group, China
- Xiaobin Wu, President and Chief Operating Officer, BeiGene, China
- Michael Yin, Chief Executive Officer, BioBAY, China
- Zhang Wenhong, Director, National Medical Centre for Infectious Diseases; Director. Department of Infectious Diseases, Fudan University Huashan Hospital, China
